Gifford Abigail R, Lawrence Julia A, Baker Laura D, Balcueva Ernie P, Case Doug, Craft Suzanne, Curtis Amy E, Griffin Leah, Groteluschen David L, Klepin Heidi D, Lesser Glenn J, Messino Michael J, Naughton Michelle, Samuel Thomas A, Rapp Steve, Sachs Bonnie, Sink Kaycee M, Williamson Jeff, Shaw Edward G
Wake Forest School of Medicine, Winston-Salem, USA.
Michigan CCOP, St. Mary's of Michigan, Saginaw, USA.
J Oncol Research. 2017;1(1). Epub 2017 Oct 20.
In this analysis we use the National Institute on Aging/Alzheimer's Association (NIA/AA) criteria to identify Mild Cognitive Impairment (MCI) in a sample of breast cancer survivors treated with chemotherapy.
Sixty women ages 39-79 on a prospective clinical trial of donepezil were assessed at baseline using a battery of standardized/validated neurocognitive measures. Cognitive status was adjudicated to identify MCI by a panel of dementia experts.
Fifty percent were not cognitively impaired, 43% met the NIA/AA criteria for MCI, 2% had dementia, and 5% could not be classified.
In this sample, nearly half of breast cancer survivors met the NIA/AA criteria for MCI. We propose these criteria be used to define cancer-related Mild Cognitive Impairment (cMCI), providing a framework for conducting additional studies to further characterize cMCI and identify clinical, imaging, and genetic factors associated with the progression of cMCI to more advanced stages of cognitive impairment.
在本分析中，我们使用美国国立衰老研究所/阿尔茨海默病协会（NIA/AA）的标准，在接受化疗的乳腺癌幸存者样本中识别轻度认知障碍（MCI）。
在一项关于多奈哌齐的前瞻性临床试验中，对60名年龄在39 - 79岁的女性进行了基线评估，使用了一系列标准化/经过验证的神经认知测量方法。由一组痴呆症专家判定认知状态以识别MCI。
50%的人没有认知障碍，43%符合NIA/AA的MCI标准，2%患有痴呆症，5%无法分类。
在这个样本中，近一半的乳腺癌幸存者符合NIA/AA的MCI标准。我们建议使用这些标准来定义癌症相关的轻度认知障碍（cMCI），为开展进一步研究提供框架，以进一步描述cMCI的特征，并识别与cMCI进展到更高级认知障碍阶段相关的临床、影像学和遗传因素。
